文献速递介入腹部DSACTMR

用于在不可切除肝细胞癌中选择经动脉化疗栓塞联合仑伐替尼方案是否加用PD-1抑制剂的预后列线图模型

Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
PubMed 文献 · Br J Radiol · 2024-01-01

回顾性分析241例不可切除肝细胞癌患者,比较经动脉化疗栓塞联合仑伐替尼(TACE-L,n=128)与联合PD-1抑制剂(TACE-L-P,n=113)的疗效与安全性,并建立预后列线图模型预测无进展生存期和总生存期,按列线图评分分层指导治疗选择。

要点

  • TACE-L-P组较TACE-L组无进展生存期延长(14.0 vs 9.0个月,P<.001),总生存期延长(24.0 vs 15.0个月,P<.001)。
  • 列线图预测无进展生存期的C-index为0.790,预测总生存期的C-index为0.749。
  • 列线图评分>9的TACE-L患者转为TACE-L-P后2年无进展生存期改善,评分≤25者转为TACE-L-P后2年总生存期更好。

核心结论

  • 与TACE-L相比,TACE-L-P在不可切除肝细胞癌患者的疗效和安全性方面显示出显著改善;列线图有助于分层治疗决策并为患者选择合适人群。

研究设计与样本

  • 回顾性研究,纳入241例接受TACE-L(n=128)或TACE-L-P(n=113)的不可切除肝细胞癌患者,基于独立临床-影像因素建立预后列线图模型,并经Cox回归分析确认用于预测无进展生存期和总生存期。

诊断标准与关键数值

  • 列线图模型区分度良好,预测无进展生存期的C-index为0.790,预测总生存期的C-index为0.749。
  • TACE-L-P组总体客观缓解率为54.0%,TACE-L组为32.8%(P=.001)。
  • TACE-L-P组与TACE-L组不良事件发生率分别为56.64%与46.09%(P=.102),≥3级不良事件发生率分别为11.50%与9.38%(P=.588),均无显著差异。
  • 列线图评分>9的TACE-L患者转为TACE-L-P后2年无进展生存期改善,评分≤25者转为TACE-L-P后2年总生存期更好。

临床应用与阅片要点

  • 列线图可用于不可切除肝细胞癌患者接受TACE-L或TACE-L-P的个体化生存获益预测,并帮助在两种方案间进行选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To establish and verify a prognostic nomogram model for selecting in unresectable hepatocellular carcinoma (uHCC) treated by transarterial chemoembolization plus lenvatinib (TACE-L) with or without PD-1 inhibitor.

METHODS: Data of 241 uHCC patients who underwent TACE-L (n = 128) and TACE-L plus PD-1 inhibitor (TACE-L-P, n = 113) were retrospectively reviewed. The differences in tumour responses, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) between two groups were compared, and a prognostic nomogram model was established based on independent clinical-radiologic factors and confirmed by Cox regression analysis for predicting PFS and OS. The treatment selection for uHCC patients was stratified by the nomogram score.

RESULTS: Compared to TACE-L, TACE-L-P presented prolonged PFS (14.0 vs. 9.0 months, P < .001), longer OS (24.0 vs. 15.0 months, P < .001), and a better overall objective response rate (54.0% vs. 32.8%, P = .001). There was no significant difference between the rate of AEs in the TACE-L-P and the TACE-L (56.64% vs. 46.09%, P = .102) and the rate of grade ≥ 3 AEs (11.50% vs. 9.38%, P = .588), respectively. The nomogram model presented good discrimination, with a C-index of 0.790 for predicting PFS and 0.749 for predicting OS. Patients who underwent TACE-L and obtained a nomogram score >9 demonstrated improved 2-year PFS when transferred to TACE-L-P, and those with a nomogram ≤25 had better 2-year OS when transferred to TACE-L-P.

CONCLUSIONS: TACE-L-P showed significant improvements in efficiency and safety for uHCC patients compared with TACE-L. The nomogram was useful for stratifying treatment decisions and selecting a suitable population for uHCC patients.

ADVANCES IN KNOWLEDGE: Prognostic nomogram model is of great value in predicting individualized survival benefits for uHCC patients after TACE-L or/and TACE-L-P. And the nomogram was helpful for selection between TACE-L-P and TACE-L among uHCC patients.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Sheng Y, Wang Q, Liu H, et al. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma. Br J Radiol. 2024. PMID: 38303541. doi:10.1093/bjr/tqae018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。